Literature DB >> 16714458

Angiogenesis: noninvasive quantitative assessment with contrast-enhanced functional US in murine model.

Olivier Lucidarme1, Yuko Kono, Jacqueline Corbeil, Sang-Hee Choi, Jean-Louis Golmard, Judith Varner, Robert F Mattrey.   

Abstract

PURPOSE: To evaluate quantitative functional ultrasonography (US) in a murine gel model by using microbubble destruction kinetics to determine whether parametric indices provided with US could help assess angiogenesis.
MATERIALS AND METHODS: Institutional Animal Subjects Committee approved experiments and procedures. In 36 normal mice, two 0.4-mL gel implants were placed subcutaneously on either side of spine. One implant contained 0.5, 1.0, or 1.5 microg human basic fibroblast growth factor (bFGF) per milliliter of gel. Functional US quantitative analysis of angiogenesis with microbubble contrast agent was performed on days 3, 6, 9, and 12; histologic data were collected. Time-intensity curve of implant was fitted to mathematic decay model to calculate fractional blood volume and fraction of blood replaced per unit of time. Microvascular density (MVD) and percentage of microvascular area (MVA) were measured after anti-CD31 staining. Spearman rank order correlation was used in analyses.
RESULTS: bFGF-containing implants induced MVD of eight, 35, 42, and 42 vessels per square millimeter on days 3, 6, 9, and 12, respectively; in controls, MVD was four vessels/mm2 (P<.05 on days 6, 9, and 12). bFGF-containing implants induced percentage MVA of 2%, 5%, 20%, and 27%, respectively; in controls, it was 0.5% (P<.05). Maximum enhancement was significantly increased in bFGF implants (23.3 gray level+/-14.1 [standard deviation]) compared with controls (11.0+/-5.5, P<.001). Implants containing bFGF showed poor correlations between fractional blood volume and MVD (r2=0.42) or percentage MVA (r2=0.51) at US. There was no correlation between microbubble velocity and MVD (r2<0.05) or percentage MVA (r2<0.13).
CONCLUSION: Functional US perfusion parameters do not correlate with current histologic indices for quantifying angiogenesis. MVD, as a histologic quantitative measurement of angiogenesis, may not be an appropriate standard for contrast-enhanced imaging that relies on perfused neovessels. Copyright (c) RSNA, 2006.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16714458     DOI: 10.1148/radiol.2392040986

Source DB:  PubMed          Journal:  Radiology        ISSN: 0033-8419            Impact factor:   11.105


  14 in total

1.  Hyposialylated IgG activates endothelial IgG receptor FcγRIIB to promote obesity-induced insulin resistance.

Authors:  Keiji Tanigaki; Anastasia Sacharidou; Jun Peng; Ken L Chambliss; Ivan S Yuhanna; Debabrata Ghosh; Mohamed Ahmed; Alexander J Szalai; Wanpen Vongpatanasin; Robert F Mattrey; Qiushi Chen; Parastoo Azadi; Ildiko Lingvay; Marina Botto; William L Holland; Jennifer J Kohler; Shashank R Sirsi; Kenneth Hoyt; Philip W Shaul; Chieko Mineo
Journal:  J Clin Invest       Date:  2017-11-27       Impact factor: 14.808

2.  Assessment of angiogenesis in rabbit orthotropic liver tumors using three-dimensional dynamic contrast-enhanced ultrasound compared with two-dimensional DCE-US.

Authors:  Qiao Zheng; Jian-Chao Zhang; Zhu Wang; Si-Min Ruan; Wei Li; Fu-Shun Pan; Li-Da Chen; Yu-Chen Zhang; Wen-Xin Wu; Xiao-Yan Xie; Ming-De Lu; Quan-Yuan Shan; Wei Wang
Journal:  Jpn J Radiol       Date:  2019-08-10       Impact factor: 2.374

3.  Contrast enhanced maximum intensity projection ultrasound imaging for assessing angiogenesis in murine glioma and breast tumor models: A comparative study.

Authors:  Flemming Forsberg; Raymond J Ro; Traci B Fox; Ji-Bin Liu; See-Ying Chiou; Magdalena Potoczek; Barry B Goldberg
Journal:  Ultrasonics       Date:  2010-11-18       Impact factor: 2.890

4.  Copper transporter 2 regulates endocytosis and controls tumor growth and sensitivity to cisplatin in vivo.

Authors:  Brian G Blair; Christopher A Larson; Preston L Adams; Paolo B Abada; Catherine E Pesce; Roohangiz Safaei; Stephen B Howell
Journal:  Mol Pharmacol       Date:  2010-10-07       Impact factor: 4.436

5.  Volumetric contrast-enhanced ultrasound imaging to assess early response to apoptosis-inducing anti-death receptor 5 antibody therapy in a breast cancer animal model.

Authors:  Kenneth Hoyt; Anna Sorace; Reshu Saini
Journal:  J Ultrasound Med       Date:  2012-11       Impact factor: 2.153

6.  Molecular imaging of vascular endothelial growth factor receptor 2 expression using targeted contrast-enhanced high-frequency ultrasonography.

Authors:  Andrej Lyshchik; Arthur C Fleischer; Jessica Huamani; Dennis E Hallahan; Marcela Brissova; John C Gore
Journal:  J Ultrasound Med       Date:  2007-11       Impact factor: 2.153

7.  Dynamic contrast-enhanced ultrasonography (D-CEUS) for the early prediction of bevacizumab efficacy in patients with metastatic colorectal cancer.

Authors:  Michele Amadori; Domenico Barone; Emanuela Scarpi; Devil Oboldi; Elena Amadori; Gianfranco Bandi; Alice Rossi; Fabio Ferroni; Angela Ragazzini; Andrea Casadei Gardini; Giovanni Luca Frassineti; Giampaolo Gavelli; Alessandro Passardi
Journal:  Eur Radiol       Date:  2018-02-07       Impact factor: 5.315

8.  A method for assessing the microvasculature in a murine tumor model using contrast-enhanced ultrasonography.

Authors:  Mary E Loveless; Xia Li; Jessica Huamani; Andrej Lyshchik; Benoit Dawant; Dennis Hallahan; John C Gore; Thomas E Yankeelov
Journal:  J Ultrasound Med       Date:  2008-12       Impact factor: 2.153

9.  Recent developments in dynamic contrast-enhanced ultrasound imaging of tumor angiogenesis.

Authors:  Reshu Saini; Kenneth Hoyt
Journal:  Imaging Med       Date:  2014-02-01

10.  Antiangiogenic effects of pazopanib in xenograft hepatocellular carcinoma models: evaluation by quantitative contrast-enhanced ultrasonography.

Authors:  Xiao-Dong Zhu; Ju-Bo Zhang; Pei-Li Fan; Yu-Quan Xiong; Peng-Yuan Zhuang; Wei Zhang; Hua-Xiang Xu; Dong-Mei Gao; Ling-Qun Kong; Lu Wang; Wei-Zhong Wu; Zhao-You Tang; Hong Ding; Hui-Chuan Sun
Journal:  BMC Cancer       Date:  2011-01-20       Impact factor: 4.430

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.